Antares Pharma Announces Pricing of Public Offering of Common Stock

  Antares Pharma Announces Pricing of Public Offering of Common Stock

Business Wire

EWING, N.J. -- October 03, 2012

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has priced a firm
commitment underwritten public offering of 12,500,000 shares of the Company’s
common stock at a purchase price to the public of $4.00 per share, resulting
in net proceeds to the Company of $47 million (before estimated offering
expenses payable by us). Jefferies & Company, Inc. and Oppenheimer and Co.
Inc. are acting as joint book-running managers for the offering. Cowen and
Company, LLC and Ladenburg Thalmann & Co. Inc. are acting as the co-managers
of the offering. The offering is expected to close on or about October 8,
2012, subject to customary closing conditions. The Company has also granted
the underwriters a 30-day option to purchase up to 1,875,000 additional shares
of common stock.

The securities described above are being offered by Antares pursuant to a
“shelf” registration statement previously filed with and declared effective by
the Securities and Exchange Commission (SEC) on July 21, 2010. A prospectus
supplement and an accompanying prospectus will be filed with the SEC in
connection with the offering. Once filed, the prospectus supplement and
accompanying prospectus may be obtained by sending a request to Jefferies &
Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 12^th Floor, New York, NY 10022, by telephone at 877-547-6340, or by
email at Prospectus_Department@Jefferies.com or by sending a request to
Oppenheimer & Co., Inc., Attention: Syndicate Prospectus Department, 85 Broad
Street, 26th Floor New York, NY, 10004, by telephone at 212-667-8563, or by
email at EquityProspectus@opco.com. Before you invest, you should read the
prospectus supplement and accompanying prospectus, the registration statement,
and the other documents that the Company has filed with the SEC for more
complete information about the Company and this offering. Investors may obtain
these documents for free by visiting the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell, or a solicitation of
an offer to buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such an offer, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products
and topical gel-based medicines. The Company's technology platforms include
VIBEX™ disposable Medi-Jet, disposable multi-use pen injectors and Vision™
reusable needle-free injectors marketed as Tjet^® and Zomajet^® by Teva
Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring),
respectively. Antares Pharma has a multi-product deal with Teva that includes
Tev-Tropin^® human growth hormone (hGH), VIBEX epinephrine and several other
products. Antares Pharma’s partnership with Ferring includes Zomacton^® hGH.
In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment
for overactive bladder that is marketed by Watson Pharmaceuticals, Inc.
Elestrin^® (estradiol gel) is FDA approved for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause, and is
marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two
facilities in the U.S. The Parenteral Products Group located in Minneapolis,
Minnesota directs the manufacturing and marketing of the Company’s reusable
needle-free injection devices and related disposables, and develops its
disposable pressure-assisted VIBEX Medi-Jet and pen injector systems. The
Company’s corporate head office and Product Development Group are located in
Ewing, New Jersey.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include statements related to a proposed
public offering of common stock Such forward-looking statements are not
guarantees of future plans and are subject to risks and uncertainties that may
cause actual results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include, among
others, changes in general market conditions and changes in the Company’s
revenue growth and difficulties or delays in the initiation, progress, or
completion of the Company’s product development plans. Additional information
concerning these and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual Report on Form
10-K for the year ended December 31, 2011, and in the Company's other periodic
reports and filings with the SEC. The Company cautions investors not to place
undue reliance on the forward-looking statements contained in this press
release. All forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company undertakes no
obligation to revise or update these forward-looking statements to reflect
events or circumstances after the date of this press release, except as
required by law.

Contact:

Antares Pharma, Inc.
Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com
 
Press spacebar to pause and continue. Press esc to stop.